pranlukast


Also found in: Wikipedia.

pranlukast

Singulair® Allergy medicine An antileukotriene that ↓ early and late response inflammation and bronchoconstriction of asthma Effect Improved FEV1, peak expiratory flow rate, Sx–eg, night awakening, ↓ use of β2 agonists Mechanism LTD4 receptor antagonism; pranlukast is used for asthma prophylaxis; it ↓ bronchial hyperresponsiveness in chronic asthma Adverse effects Zafirkulast ↑ in PT in Pts on warfarin. See Antileukotrienes, Asthma.
References in periodicals archive ?
Takeuchi, "Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate," International Journal of Pharmaceutics, vol.
Drug Method Key ingredients PSD ([micro]m) Pranlukast SD Pharmatose 200 M and <90 hydrate Pharmatose 325 M Human serum SD Albumin : lactose: DPPC 6.50 albumin (30 : 10 : 60) SS SD Lactochem crystals 7772 Budesonide SD [alpha]-LM >230 Drug Device and flow % FPF References rate (l/min) Pranlukast Spinhaler[R] 28.5 [+ or -] 3.1 [35] hydrate and 60 Human serum Spinhaler and 41 [+ or -] 5.0 [36] albumin 28.3 SS Cyclohaler and 31.3 [+ or -] 1.3 [37] 60 Budesonide Thaifun[R] 31.0 [+ or -] 5.1 [38] * Taifun is a multiple dose, reservoir-based DPI.
Indeed, the CysLTR-1 antagonist pranlukast did not reduce the accumulation of microglia in the ischemic cerebral cortex [49], while HAMI 3379 significantly attenuated the number of microglia in the ischemic core and in the boundary zone [50].
Pranlukast inhibited acute, subacute, and chronic ischemic injury in the brains of mice and rats after focal cerebral ischemia [15,49,65,78].
employed EA.Hy926 cells to establish [H.sub.2][O.sub.2]-mediated oxidative injury model for evaluation of the protective effects of pranlukast, which was associated with the inhibition of ROS-mediated collapse of mitochondrial membrane potential [54].
This is similar to unpublished data from our group and other studies indicating that systemic montelukast does not prevent PTZ-induced seizures in mice, as well as evidence that montelukast and pranlukast cross the BBB poorly.
Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.
[7] Other treatment modalities include Altrans retinoic acid, Imatinib, Pranlukast, Cetrizine and Intravenous Immunogobulins.
Pranlukast was introduced for clinical application in Japan in 1995 and is currently marketed in this and several other Asian countries.
carbama-zepina, ciclosporina, cilostazol, cisapride, clindamicina, clomipramina, clonazpam, clopidogrel, c ocaina, dapsona, dexameta- sona, dextrometorfan, diazepam, diltiazem, eritromicina, estrogenos, etosuximida, fluticasona, imipramina, indinavir, isradi- pino, ketoconazol, lansoprazol, lidocaina, lovastatina, mibefradil, midazolam, nifedi-pina, nimodipina, paricalcitol, pioglitazona, pranlukast, pravastatina, prednisolona, quinina, rifampicina, ranolaxine, repagli-nida, rimonabant, ritonavir, sertralina, sildenafil, simvastatina, sirolimus, sitaglip-tina, tacrolimus, tadalofilo, tamsulosina, terfenadina, pruebaosterona, triazolam, valdenafil, verapamilo, warfarina, zolpidem.
En el futuro se vislumbran otros medicamentos antiasmaticos antagonistas de leucotrienos como el Pranlukast que promete ser altamente efectivo y seguro en la prevencion y el tratamiento del asma.
Zafirlukast and pranlukast are both orally active antagonists of LTD4 and represent the furthest advanced of all the anti-leukotriene drugs currently being developed.